Empliciti, also known as Elotuzumab, is a monoclonal antibody that is used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells. It is specifically designed to target the SLAMF7 protein, which is found on the surface of myeloma cells and natural killer cells.
